Literature DB >> 28131751

18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer.

Frederik L Giesel1, Claudia Kesch2, Mijin Yun3, Jens Cardinale4, Uwe Haberkorn5, Klaus Kopka4, Clemens Kratochwil5, Boris A Hadaschik2.   

Abstract

Entities:  

Keywords:  Biochemical recurrence; Imaging; Positron emission tomography; Radiotracer-labeled prostate-specific membrane antigen; Staging

Mesh：

Substances：

Year:  2016        PMID： 28131751     DOI： 10.1016/j.clgc.2016.12.029

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  20 in total

1.  68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Authors:  Maria Vinsensia; Peter L Chyoke; Boris Hadaschik; Tim Holland-Letz; Jan Moltz; Klaus Kopka; Isabel Rauscher; Walter Mier; Markus Schwaiger; Uwe Haberkorn; Tobias Mauer; Clemens Kratochwil; Matthias Eiber; Frederik L Giesel
Journal:  J Nucl Med       Date:  2017-06-21       Impact factor: 10.057

2.  The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.

Authors:  Can Öbek; Tünkut Doğanca; Emre Demirci; Meltem Ocak; Ali Rıza Kural; Asıf Yıldırım; Uğur Yücetaş; Çetin Demirdağ; Sarper M Erdoğan; Levent Kabasakal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-18       Impact factor: 9.236

3.  18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics.

Authors:  Kambiz Rahbar; Ali Afshar-Oromieh; Martin Bögemann; Stefan Wagner; Michael Schäfers; Lars Stegger; Matthias Weckesser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-14       Impact factor: 9.236

4.  Management of biochemically recurrent prostate cancer: molecular imaging perspective.

Authors:  Alberto Martinez Lorca
Journal:  World J Urol       Date:  2017-11-13       Impact factor: 4.226

Review 5.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 6.  Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer.

Authors:  Nicholas M Donin; Robert E Reiter
Journal:  J Nucl Med       Date:  2017-10-06       Impact factor: 10.057

Review 7.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

8.  Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer.

Authors:  Jens Cardinale; René Martin; Yvonne Remde; Martin Schäfer; Antje Hienzsch; Sandra Hübner; Anna-Maria Zerges; Heike Marx; Ronny Hesse; Klaus Weber; Rene Smits; Alexander Hoepping; Marco Müller; Oliver C Neels; Klaus Kopka
Journal:  Pharmaceuticals (Basel)       Date:  2017-09-27

Review 9.  Molecular Imaging, How Close to Clinical Precision Medicine in Lung, Brain, Prostate and Breast Cancers.

Authors:  Zhaoguo Han; Mingxing Ke; Xiang Liu; Jing Wang; Zhengqi Guan; Lina Qiao; Zhexi Wu; Yingying Sun; Xilin Sun
Journal:  Mol Imaging Biol       Date:  2021-07-16       Impact factor: 3.488

10.  The Diagnostic Role of 18F-Choline, 18F-Fluciclovine and 18F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis.

Authors:  Rang Wang; Guohua Shen; Mingxing Huang; Rong Tian
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.